Biography

Research

Journal Articles

• Gögenur, M., Hickish, T. et al., 2024. Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy Post Hoc Analysis of the SCOT Randomized Clinical Trial. JAMA Surgery, 159 (8), 865-871.
  • more information
• Glasbey, J. et al., 2024. Risk of Bowel Obstruction in Patients Undergoing Neoadjuvant Chemotherapy for High-risk Colon Cancer: A Nested Case-control-matched Analysis of an International, Multicenter, Randomized Controlled Trial (FOxTROT). Annals of Surgery, 280 (2), 283-293.
  • more information
• Abraham, J.E., Hickish, T. et al., 2024. The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer. Nature, 629 (8014), 1142-1148.
  • more information
• Holt, S., Hickish, T. et al., 2024. A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer. British Journal of Cancer, 130 (7), 1149-1156.
  • more information
• Coakley, M., Hickish, T. et al., 2024. Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research, 30 (4), 895-903.
  • more information
• Turner, N.C., Hickish, T. et al., 2023. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. Annals of Oncology, 34 (2), 200-211.
  • more information
• Ring, A., Hickish, T. et al., 2023. Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010). Clinical Cancer Research, 29 (23), 4751-4759.
  • more information
• Geyer, C.E. et al., 2022. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Annals of Oncology, 33 (12), 1250-1268.
  • more information
• Hickish, T. et al., 2022. Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial. Breast Cancer Research and Treatment, 192 (3), 593-602.
  • more information
  • view in BU repository
• Tutt, A.N.J. et al., 2021. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med, 384 (25), 2394-2405.
  • more information
• Pritchard, C., Birch, B., Hickish, T. and Rosenorn-Lanng, E., 2021. Comparing Total Neoplasms, Breast & Prostate Cancer Mortality Rates of the UK and 20 Major Developed Countries 1989-91 v 2013- 15 - Identifying Progress. Archive Internal Medical Research, 4 (1), 19-30.
  • more information
  • view in BU repository
• Bridgewater, J.A., Hickish, T. et al., 2020. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. The Lancet Oncology, 21 (3), 398-411.
  • more information
  • view in BU repository
• Mansbridge, C., Simmonds, P., Murray, N., Davies, A., Stanton, L., Chinnery, F., Archer, C., Barrett-Lee, P., Hickish, T. and Crabb, S., 2020. A phase 2 open-label study of carboplatin in combination with gemcitabine as a dose-dense schedule in patients with locally advanced or metastatic breast cancer that are resistant to anthracyclines and taxanes. F1000Research, 9.
  • more information
• Ivesono, T., Hickish, T. et al., 2019. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage ii and iii colorectal cancer: 3-year follow-up of the scot non-inferiority rct. Health Technology Assessment, 23 (64), 1-88.
  • more information
• Jones, R.P. et al., 2019. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. JAMA Surg, 154 (11), 1038-1048.
  • more information
• Huober, J., Hickish, T. et al., 2019. Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. European Journal of Cancer, 118, 169-177.
  • more information
• Auclin, E., André, T., Taieb, J., Banzi, M., Van Laethem, J.L., Tabernero, J., Hickish, T., de Gramont, A. and Vernerey, D., 2019. Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial. British Journal of Cancer, 121 (4), 312-317.
  • more information
• Primrose, J.N., Hickish, T. et al., 2019. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. The Lancet Oncology, 20 (5), 663-673.
  • more information
• Kurzrock, R., Hickish, T., Wyrwicz, L., Saunders, M., Wu, Q., Stecher, M., Mohanty, P., Dinarello, C.A. and Simard, J., 2019. Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer. OncoImmunology, 8 (3).
  • more information
• Auclin, E., Hickish, T. et al., 2019. Carcinoembryonic antigen levels and survival in stage III colon cancer: Post hoc analysis of the MOSAIC and PETACC-8 trials. Cancer Epidemiology Biomarkers and Prevention, 28 (7), 1153-1161.
  • more information
• Robles-Zurita, J., Hickish, T. et al., 2018. SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. British Journal of Cancer, 119 (11), 1332-1338.
  • more information
  • view in BU repository
• Cidon, E.U., Martinez, P.A. and Hickish, T., 2018. Gemcitabine-induced haemolytic uremic syndrome, although infrequent, can it be prevented: A case report and review of literatureN. World Journal of Clinical Cases, 6 (12), 531-537.
  • more information
  • view in BU repository
• Jankowski, J.A.Z. et al., 2018. Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. Lancet, 392 (10145), 400-408.
  • more information
• Iveson, T.J., Hickish, T. et al., 2018. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. The Lancet Oncology, 19 (4), 562-578.
  • more information
  • view in BU repository
• Pritchard, C., Williams, R., Hickish, T. and Wallace, M., 2018. A Population-Based Study Comparing Child (0-4) and Adult (55-74) Mortality, GDP-Expenditure on-Health and Relative Poverty in the UK and Developed Countries 1989-2014. Some Challenging Outcomes. Archives of Community Medicine and Public Health, 3 (2), 77-84.
  • more information
  • view in BU repository
• Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Waldron-Lynch, M., Eng-Wong, J., Kirk, S. and Cortés, J., 2018. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. European Journal of Cancer, 89, 27-35.
  • more information
• McLaughlin, P., Mactier, H., Gillis, C., Hickish, T., Parker, A., Liang, W.J. and Osselton, M.D., 2017. Increased DNA Methylation of ABCB1, CYP2D6, and OPRM1 Genes in Newborn Infants of Methadone-Maintained Opioid-Dependent Mothers. Journal of Pediatrics, 190, 180-184.e1.
  • more information
  • view in BU repository
• Emile, J.F. et al., 2017. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. European Journal of Cancer, 82, 16-24.
  • more information
• Gligorov, J. et al., 2017. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. European Journal of Cancer, 82, 237-246.
  • more information
• Wasan, H.S., Hickish, T. et al., 2017. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. The Lancet Oncology, 18 (9), 1159-1171.
  • more information
• Earl, H.M., Hickish, T. et al., 2017. Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis trial. Annals of Oncology, 28 (8), 1817-1824.
  • more information
  • view in BU repository
• Thomas, J.S.J., Hickish, T. et al., 2017. Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial. Modern Pathology, 30 (8), 1069-1077.
  • more information
• Davidson, M., Chau, I., Cunningham, D., Khabra, K., Iveson, T., Hickish, T., Seymour, M. and Starling, N., 2017. Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer. World Journal of Gastrointestinal Oncology, 9 (8), 333-340.
  • more information
  • view in BU repository
• Earl, H.M., Hickish, T. et al., 2017. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. LANCET ONCOLOGY, 18 (6), 755-769.
  • more information
• Kurzrock, R. et al., 2017. Pre-treatment endogenous interleukin-1 receptor antagonist (IL-1Ra) levels in metastatic colorectal cancer (mCRC) patients are associated with clinical outcomes after anti-interleukin-1a therapy (MABp1). Annals of oncology : official journal of the European Society for Medical Oncology, 28, iii98-iii99.
  • more information
• Una Cidon, E., Alonso, P. and Hickish, T., 2017. Sensitivity and specificity of DPD deficiency screening test to predict capecitabine serious toxicities. Annals of oncology : official journal of the European Society for Medical Oncology, 28, iii119-iii120.
  • more information
• Middleton, G., Hickish, T. et al., 2017. Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. The Lancet Oncology, 18 (4), 486-499.
  • more information
  • view in BU repository
• Hickish, T. et al., 2017. MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Oncology, 18 (2), 192-201.
  • more information
  • view in BU repository
• Pugh, S.A., Hickish, T. et al., 2016. Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study. British Journal of Cancer, 115 (4), 420-424.
  • more information
  • view in BU repository
• Pritchard, C., Hickish, T., Rosenorn-Lanng, E. and Wallace, M., 2016. Comparing UK and 20 Western countries' efficiency in reducing adult (55-74) cancer and total mortality rates 1989-2010: Cause for cautious celebration? A population-based study. JRSM Open, 7 (6), 2054270416635036.
  • more information
  • view in BU repository
• Saunders, E.J. et al., 2016. Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. Br J Cancer, 114 (8), 945-952.
  • more information
• Ali, H.R., Hickish, T. et al., 2016. Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Research, 18 (1).
  • more information
• André, T., Hickish, T. et al., 2015. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: Updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. Journal of Clinical Oncology, 33 (35), 4176-4187.
  • more information
• Sclafani, F., Hickish, T. et al., 2015. Short- and long-term quality of life and bowel function in patients with MRI-defined, high-risk, locally advanced rectal cancer treated with an intensified neoadjuvant strategy in the randomized phase 2 EXPERT-C trial. International Journal of Radiation Oncology Biology Physics, 93 (2), 303-312.
  • more information
• Amin Al Olama, A. et al., 2015. Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Hum Mol Genet, 24 (19), 5589-5602.
  • more information
• Primrose, J.N., Hickish, T. et al., 2015. Cetuximab is contraindicated in the perioperative treatment of colorectal liver metastases. Journal of Clinical Oncology, 33 (21), 2405-2406.
  • more information
• Earl, H.M., Hickish, T. et al., 2015. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncol, 16 (6), 656-666.
  • more information
• Earl, H. et al., 2015. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncology.
  • more information
• Abbey, G., Thompson, S.B.N., Heathcote, D. and Hickish, T., 2015. A meta-analysis of prevalence and moderating factors data for cancer-related post-traumatic stress disorder. Psych-Oncology, Volume 24, Issue 4 April 2015 Pages 371–381 (4), 7-7.
  • more information
• PETACC-8 study investigators, Hickish, T. et al., 2015. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. Ann Oncol, 26 (4), 822-825.
  • more information
• Purandare, L. and Hickish, T., 2015. Acceptability and safety of telemedicine to assess patients before chemotherapy. Cancer Nursing Practice, 14 (6), 20-24.
  • more information
• Gillis, C., McLaughlin, P., Osselton, D., Hickish, T. and Mactier, H., 2015. Genetic and epigenetic variations and gene methylation in infants exposed to methadone in-utero. British Association of Perinatal Medicine; Arch Dis Child.
  • more information
• Sclafani, F., Hickish, T. et al., 2014. Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial. International Journal of Radiation Oncology Biology Physics.
  • more information
• Mishu, M., Dubey, V.N., Hickish, TH and Cole, J., 2014. A Review on Pressure Ulcer: Aetiology, Cost, Detection and Prevention Systems. International Journal of Engineering Sciences & Research Technology, 3 (9), 419-428.
  • more information
  • view in BU repository
• Middleton, G., Hickish, T. et al., 2014. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol, 15 (8), 829-840.
  • more information
• Taieb, J. et al., 2014. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol, 15 (8), 862-873.
  • more information
• Masters, B., Hickish, T. and Cidon, E.U., 2014. A midline for oxaliplatin infusion: the myth of safety devices. BMJ Case Rep, 2014.
  • more information
• Mishu, M.C., Dubey, V.N., Hickish, T. and Cole, J., 2014. Mathematical Modelling of Different Types of Body Support Surface for Pressure Ulcer Prevention. International Journal of Medical, Pharmaceutical Science and Engineering, 8 (5), 209-214.
  • more information
  • view in BU repository
• Yao, C., Nash, G.F. and Hickish, T., 2014. Management of colorectal cancer and diabetes. J R Soc Med, 107 (3), 103-109.
  • more information
• Molife, L.R., Hickish, T. et al., 2014. Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. Future Oncol, 10 (2), 219-231.
  • more information
• Earl, H.M., Hickish, T. et al., 2014. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial. Lancet Oncol, 15 (2), 201-212.
  • more information
• Pan, J.J., Chang, J., Yang, X., Zhang, J.J., Qureshi, T., Howell, R., Hickish, T. and Liang, H., 2014. Virtual reality training and assessment in laparoscopic rectum surgery. International Journal of Medical Robotics and Computer Assisted Surgery.
  • more information
  • view in BU repository
• Primrose, J., Hickish, T. et al., 2014. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: The New EPOC randomised controlled trial. The Lancet Oncology, 15 (6), 601-611.
  • more information
• Hickish, T. et al., 2014. A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. European Journal of Cancer, 50, 3136-3144.
  • more information
• Wasan, H. et al., 2014. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncology, 15 (6), 631-639.
  • more information
• Hickish, T. et al., 2014. A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. European Journal of Cancer, 50, 3136-3144.
  • more information
• Schneeweiss, A., Hickish, T. et al., 2013. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol, 24 (9), 2278-2284.
  • more information
• Awada, A., Hickish, T. et al., 2013. The ENCHANT-1 trial (NCT01677455): An open label multicenter phase 2 proof of concept study evaluating first line ganetespib monotherapy in women with metastatic HER2 positive or triple negative obreast cancer (TNBC). CANCER RESEARCH, 73.
  • more information
• Agbamu, D.A., Hickish, T.F.G. et al., 2012. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: The pilot phase of a randomised controlled trial. The Lancet Oncology, 13 (11), 1152-1160.
  • more information
• Hickish, T. and Farmery, A.D., 2012. Acid-base physiology: New concepts. Anaesthesia and Intensive Care Medicine, 13 (11), 567-572.
  • more information
• Nash, G.F., Turner, K.J., Hickish, T., Smith, J., Chand, M. and Moran, B.J., 2012. Interactions in the aetiology, presentation and management of synchronous and metachronous adenocarcinoma of the prostate and rectum. Ann R Coll Surg Engl, 94 (7), 456-462.
  • more information
• Tournigand, C., Hickish, T. et al., 2012. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol, 30 (27), 3353-3360.
  • more information
• Dunlop, M.G. et al., 2012. Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nature Genetics, 44 (7), 770-776.
  • more information
• Lin, N.U., Hickish, T. et al., 2012. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Research and Treatment, 133 (3), 1057-1065.
  • more information
• Dunlop, M.G. et al., 2012. Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet, 44 (7), 770-776.
  • more information
• Moyers-Ruiz, L., Hickish, T. and Thompson, S.B.N., 2012. Prospective and working memory decline as a result of impaired sleep and/or impaired blood glucose in breast cancer patients during chemotherapy treatment. Journal of Clinical Oncology, 30 ((Suppl), abstr), TPS9148.
  • more information
• James, N.D. et al., 2012. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med, 366 (16), 1477-1488.
  • more information
• Baselga, J. et al., 2012. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet, 379 (9816), 633-640.
  • more information
• Moyers-Ruiz, L., Thompson, S. and Hickish, T., 2012. Investigation Of Prospective And Working Memory Decline And The Impact Of Impaired Sleep And/Or Glucose Metabolism In Recently Diagnosed Breast Cancer Patients Undergoing Chemotherapy: A Longitudinal Study. PSYCHO-ONCOLOGY, 21, 6.
  • more information
• Moyers-Ruiz, L., Hickish, T. and Thompson, S.B.N., 2012. Prospective and working memory decline as a result of impaired sleep and/or impaired blood glucose in breast cancer patients during chemotherapy treatment. Journal of Clinical Oncology, 30 (Suppl), TPS9148.
  • more information
• Schroeder, J., Dubey, V., Hickish, T. and Cole, J., 2012. Wearable Electrocutaneous Feedback System: A Smart Device to Compensate for Sensation Loss. Journal of Medical Devices, 6 (1).
  • more information
• Schroeder, J., Dubey, V., Hickish, T. and Cole, J., 2012. Case Study on Repeatability of a Threshold-Based Calibration Method for Electrocutaneous Feedback Systems. Journal of Medical Devices, 6 (1).
  • more information
• Regan, M.M. et al., 2011. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol, 12 (12), 1101-1108.
  • more information
• Thompson, S., Eccleston, L. and Hickish, T.F., 2011. Post-traumatic stress disorder on cancer survivors: recognising and acknowledging the symptoms. WMC Oncology, 2, 1-16.
  • more information
• Adams, R.A., Hickish, T. et al., 2011. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol, 12 (7), 642-653.
  • more information
• Maughan, T.S. et al., 2011. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet, 377 (9783), 2103-2114.
  • more information
• Seymour, M.T. et al., 2011. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet, 377 (9779), 1749-1759.
  • more information
• Seymour, M.T., Hickish, T. et al., 2011. Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). J Clin Oncol, 29 (15_suppl), 3523.
  • more information
• Pritchard, C. and Hickish, T.F., 2011. Cancer survival in Australia, Canada, Denmark, Norway, Sweden and the UK. Lancet, 377, 1149.
  • more information
• Pritchard, C. and Hickish, T.F., 2011. Comparing cancer mortality and GDP health expenditure in England and Wales with other major developed countries from 1979 to 2006. British Journal of Cancer.
  • more information
  • view in BU repository
• Pan, J., Chang, J., Yang, X., Zhang, J.J., Qureshi, T. and Howell, R., 2011. A Medical VR Simulator in Laparoscopic Rectum Surgery. Cyber Therapy and Rehabilitation, 4, 19-20.
  • more information
• Valle, J. et al., 2010. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med, 362 (14), 1273-1281.
  • more information
• Houston, S., Grieve, R.J., Hickish, T.F., Percival, F. and Hamilton, E., 2010. Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study. Journal of Medical Economics, 13, 162-167.
  • more information
• Sirohi, B., Hickish, T.F. et al., 2010. A randomized comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: the TRAFIC trial. Annals of Oncology, 21, 1623-1629.
  • more information
• Cunningham, D. and Hickish, T.F., 2010. A multicentre phase II study of capecitabine, oxaliplatin plus bevacizumab as peri-operative treatment for patients with poor risk colorectal liver-only metastases unsuitable for upfront resection. Journal of Clinical Oncology.
  • more information
• Pan, J., Chang, J., Yang, X., Zhang, J., Qureshi, T., Howell, R.D. and Hickish, T.F., 2010. Graphic and haptic simulation system for virtual laparoscopic rectum surgery. International Journal of Medical Robotics and Computer Assisted Surgery, 7.
  • more information
• Teixeira, L., Hickish, T., Tournigand, C., Bachet, J., Bonetti, A., Rivera, F., Boni, C., Tabernero, J., Andre, T. and De Gramont, A., 2010. Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): A new analysis of the MOSAIC trial according to risk factors. JOURNAL OF CLINICAL ONCOLOGY, 28 (15).
  • more information
• Toumigand, C., Andre, T., Bachet, J., Teixeira, L., Boni, C., Clingan, P.R., Hickish, T., Tabernero, J. and De Gramont, A., 2010. FOLFOX4 as adjuvant therapy in elderly patients (pts) with colon cancer (CC): Subgroup analysis of the MOSAIC trial. JOURNAL OF CLINICAL ONCOLOGY, 28 (15).
  • more information
• Al Olama, A.A. et al., 2009. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet, 41 (10), 1058-1060.
  • more information
• Eeles, R.A. et al., 2009. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet, 41 (10), 1116-1121.
  • more information
• BIG 1-98 Collaborative Group et al., 2009. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med, 361 (8), 766-776.
  • more information
• Giobbie-Hurder, A., Price, K.N., Gelber, R.D., International Breast Cancer Study Group and BIG 1-98 Collaborative Group, 2009. Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Clin Trials, 6 (3), 272-287.
  • more information
• Hickish, T., Wheatley, D., Lin, N., Carey, L., Houston, S., Mendelson, D., Solca, F., Uttenreuther-Fischer, M., Jones, H. and Winer, E., 2009. Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab. J Clin Oncol, 27 (15_suppl), 1023.
  • more information
• Earl, H.M., Hickish, T. et al., 2009. Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR). J Clin Oncol, 27 (15_suppl), 522.
  • more information
• Ellis, P. et al., 2009. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet, 373 (9676), 1681-1692.
  • more information
• Chau, I., Norman, A.R., Cunningham, D., Oates, J., Hawkins, R., Iveson, T., Nicolson, M., Harper, P., Seymour, M. and Hickish, T., 2009. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials. Ann Oncol, 20 (5), 885-891.
  • more information
• Hickish, T.F., Astras, G., Thomas, P., Penfold, S., Purandare, L. and Kerr, D., 2009. Glucose intolerance during adjuvant chemotherapy for breast cancer. Correspondence. Journal of the National Cancer Institute, 101, 537.
  • more information
• Andre, T., Hickish, T.F. et al., 2009. Improved overall survival with oxaliplatin, fluorouracil and leucovorin as adjuvant treatment in stage II / III colon cancer: update from a randomised controlled trial. Journal of Clinical Oncology, 27, 3109-3116.
  • more information
• Boni, C., Andre, T., Banzi, M.C., Hickish, T.F., Tabernero, J., Clingan, P., Chibaudel, B. and De Gramont, A., 2009. Similarities and differences between the adjuvant oxaliplatin-based trials, MOSAIC and NSABP C-07. Current Colorectal Cancer Reports, 5, 166-170.
  • more information
• Viale, G. et al., 2008. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol, 26 (34), 5569-5575.
  • more information
• Pritchard, C. and Hickish, T.F., 2008. Changes in Cancer Incidence and Mortality in England & Wales and a comparison of cancer deaths in the Major Developed Countries by Age and Sex 1979-2002 in context of GDP Expenditure on Health. ecancermedicalscience, 2, 1-18.
  • more information
• Hemandas, A.K., Robson, N.K., Hickish, T.F. and Talbot, R.W., 2008. Colorectal tubulovillous adenomas identified on fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography scans. Colorectal Disease, 10, 386-389.
  • more information
• Chand, M., Moore, P.J., Clarke, A.D., Nash, G.F. and Hickisk, T., 2007. A diagnostic dilemma following risk-reducing surgery for BRCA1 mutation - A case report of primary papillary serous carcinoma presenting as sigmoid cancer. World Journal of Surgical Oncology, 5.
  • more information
• Hickish, T., Chau, I., Massey, A., Higgins, L., Osborne, R., Botwood, N., Swaisland, A. and Cunningham, D.C., 2006. Gefitinib and irinotecan in patients with fluoropyrimidine-refractory irinotecan-naïve advanced colorectal cancer (CRC): dose-finding, pharmacokinetics, safety and efficacy. J Clin Oncol, 24 (18_suppl), 13520.
  • more information
• Cassidy, J., Bjarnason, G.A., Hickish, T., Topham, C., Provencio, M., Bodoky, G., Landherr, L., Koralewski, P., Lopez-Vivanco, G. and Said, G., 2006. Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC). J Clin Oncol, 24 (18_suppl), 3507.
  • more information
• Chau, I., Hickish, T.F. et al., 2006. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. British Journal of Cancer, 94, 1107-1115.
  • more information
• Trumper, M., Ross, P.J., Cunningham, D., Norman, A.R., Hawkins, R., Seymour, M.T.J., Harper, P., Iveson, T.J., Nicolson, M.C. and Hickish, T.F., 2006. Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials. European Journal of Cancer, 42, 827-834.
  • more information
• Hickish, T.F., 2006. Administration of cetuximab in managing colorectal cancer. Cancer Nursing Practice, 5, 28-29.
  • more information
• Chau, I., Cunningham, D., Hickish, T.F., Massey, A., Higgins, L., Osborne, R.J., Botwood, N. and Swaisland, A., 2006. Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study. Annals of Oncology, 18, 730-737.
  • more information
• Chau, I., Hickish, T.F. et al., 2005. Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer. European Journal of Cancer, 41, 1551-1559.
  • more information
• Chua, S., Hickish, T.F. et al., 2005. Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Annals of Oncology, 16, 1435-1441.
  • more information
• Sumpter, K., Hickish, T.F. et al., 2005. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. British Journal of Cancer, 92, 1976-1983.
  • more information
• Chau, I., Hickish, T. et al., 2005. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol, 16 (4), 549-557.
  • more information
• Mandalà, M., Ferretti, G., Barni, S., De Gramont, A., André, T. and Hickish, T., 2004. Oxaliplatin in colon cancer [3] (multiple letters). New England Journal of Medicine, 351 (16), 1691-1692.
  • more information
• Starling, N., Chau, I., Norman, A.R., Tait, D., Iveson, T., Hill, M., Hickish, T., Lofts, F., Jodrell, D. and Cunningham, D., 2004. A randomised comparison between six months of bolus fluorouracil (5-FU)/leucovorin (LV) and twelve weeks of protracted venous infusion (PVI) 5-FU as adjuvant treatment in colorectal cancer: An update with 5 years' follow-up. J Clin Oncol, 22 (14_suppl), 3523.
  • more information
• Trumper, M.J., Norman, A.R., Ross, P.J., Cunningham, D., Hawkins, R., Seymour, M., Harper, P., Iveson, T., Nicholson, M. and Hickish, T., 2004. Patients aged 70 or older (≥ 70) with advanced oesophagogastric cancer (OGC) experience similar benefits from palliative chemotherapy compared to younger patients. J Clin Oncol, 22 (14_suppl), 4018.
  • more information
• Hickish, T., Boni, C., Navarro, M., Tabernero, J., Topham, C., Bonetti, A., Clingan, P., Figer, A., Andre, T. and De Gramont, A., 2004. FOLFOX4 as adjuvant treatment for stage II colon cancer (CC): Subpopulation data from the MOSAIC trial. J Clin Oncol, 22 (14_suppl), 3619.
  • more information
• Norman, A.R., Chau, I., Iveson, T., Hill, M., Hickish, T., Lofts, F., Jodrell, D., Shellito, P., Oates, J. and Cunningham, D., 2004. Longitudinal quality of life (QoL) and quality adjusted survival (QAS) in a randomised controlled trial (RCT) comparing bolus (24 weeks) vs. protracted venous infusion (PVI 12 weeks) 5-FU as adjuvant chemotherapy for colorectal cancer (CRC). J Clin Oncol, 22 (14_suppl), 3625.
  • more information
• Andre, T., Hickish, T.F. et al., 2004. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. New England Journal of Medicine, 350, 2343-2351.
  • more information
• Papazisis, K.T., Hickish, T. et al., 2004. Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK. International Journal of Clinical Practice, 58 (6), 581-586.
  • more information
• Smith, I.E., Hickish, T.F. et al., 2004. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Annals of Oncology, 15, 751-758.
  • more information
• Price, T.J., Hickish, T.F. et al., 2004. Phase III Study of Mitomycin-C with Protracted Venous Infusion or Circadian-Timed Infusion of 5-Fluorouracil in Advanced Colorectal Carcinoma. Clinical Colorectal Cancer, 3, 235-242.
  • more information
• O'Brien, M.E.R., Hickish, T. et al., 2004. SRL 172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: Phase III results. Annals of Oncology, 15 (6), 906-914.
  • more information
• Hickish, T., Boni, C., Navarro, M., Tabernero, J., Bonetti, A., Clingan, P., Figer, A., Andre, T. and de Gramont, A., 2004. Stage II patients in the "MOSAIC" trial evaluating Oxaliplatin/5FU/LV as adjuvant treatment of colon cancer: a subpopulation analysis. ANNALS OF ONCOLOGY, 15, 76.
  • more information
• Ross, P.J., Trumper, M., Norman, A.R., Hawkins, R., Seymour, M., Harper, P.G., Iveson, T., Nicolson, M., Hickish, T. and Cunningham, D., 2004. An analysis of the outcome to palliative chemotherapy for oesophagogastric (OGC) cancer in patients aged 70 years and older (≥70) with younger patients. ANNALS OF ONCOLOGY, 15, 230.
  • more information
• de Gramont, A., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Bonetti, A., Clingan, P., Marceau-Suissa, J. and Andre, T., 2004. Oxaliplatin/5FU/LV in stage II and III Colon Cancer: Updated results (as of January 04) for efficacy and neurotoxicity of the MOSAIC trial. ANNALS OF ONCOLOGY, 15, 73.
  • more information
• Saini, A., Hickish, T.F. et al., 2003. Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. British Journal Of Cancer, 88, 1859-1866.
  • more information
• Assersohn, L., Norman, A.R., Cunningham, D., Iveson, T.J., Seymour, M.T.J., Hickish, T.F., Massey, A., Prior, Y. and Hilla, M.E., 2003. A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary. European Journal of Cancer, 39, 1121-1128.
  • more information
• Johnston, S.R.D. et al., 2003. Phase II Study of the Efficacy and Tolerability of Two Dosing Regimens of the Farnesyl Transferase Inhibitor, R115777, in Advanced Breast Cancer. Journal of Clinical Oncology, 21, 2492-2499.
  • more information
• Maisey, N.R., Hickish, T.F. et al., 2002. Multicenter Randomized Phase III Trial Comparing Protracted Venous Infusion (PVI) Fluorouracil (5-FU) With PVI 5-FU Plus Mitomycin in Inoperable Pancreatic Cancer. Journal of Clinical Oncology, 20, 3130-3136.
  • more information
• Ross, P.J., Hickish, T.F. et al., 2002. Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer. Journal of Clinical Oncology, 20, 1996-2004.
  • more information
• Tebbutt, N.C., Hickish, T. et al., 2002. A muticentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Annals of Oncology, 13 (10), 1568-1575.
  • more information
• Dowsett, M., Cuzick, J., Howell, A., Jackson, I. and ATAC Trialists' Group, 2001. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. Br J Cancer, 85 (3), 317-324.
  • more information
• Donnelly, J., Parham, D.M., Hickish, T.F., Chan, H.Y. and Skene, A.I., 2001. Axillary lymph node scarring and the association with tumour response following neoadjuvant chemoendocrine therapy for breast cancer. The Breast, 10, 61-66.
  • more information
• Smith, I.E., O Brien, M.E.R., Talbot, D.C., Nicolson, M.C., Mansi, J.L., Hickish, T.F., Norton, A. and Ashley, S., 2001. Duration of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A Randomized Trial of Three Versus Six Courses of Mitomycin, Vinblastine, and Cisplatin. Journal of Clinical Oncology, 19, 1336-1343.
  • more information
• Smith, I.E., Johnston, S.R.D., O Brien, M.E.R., Hickish, T.F., de Boer, R.H., Norton, A., Cirkel, D.T. and Barton, C.M., 2000. Low-Dose Oral Fluorouracil With Eniluracil as First-Line Chemotherapy Against Advanced Breast Cancer: A Phase II Study. Journal of Clinical Oncology, 18, 2378-2384.
  • more information
• Smith, I.E., A'Hern, R.P., Ebbs, S., Howell, A., Hickish, T., O'Brien, M., Robinson, A. and Wilson, C., 2000. Preoperative continuous infusional (epirubicin, cisplatin and infusional 5 FU) v. conventional AC chemotherapy for early breast cancer: As phase III randomised trial. BRITISH JOURNAL OF CANCER, 83, 2.
  • more information
• Iveson, T.J., Hickish, T., Schmitt, C. and Van Cutsem, E., 1999. Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. Eur J Cancer, 35 (13), 1796-1804.
  • more information
• Waters, J.S., Hickish, T. et al., 1999. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer, 80 (1-2), 269-272.
  • more information
• Ross, P., Hickish, T. et al., 1999. Results of a randomised trial comparing ECF with MCF in advanced oesophago-gastric cancer. EUROPEAN JOURNAL OF CANCER, 35, S137.
  • more information
• Price, T., Cunningham, D., Hickish, T., Tait, D., Norman, A., Ross, P.J., Middleton, G., Ford, H.E.R., Sumpter, K. and Hill, M., 1999. Dose intensification of 5 fluorouracil by chronomodulation in a phase III trial for advanced colorectal carcinoma. BRITISH JOURNAL OF CANCER, 80, 20.
  • more information
• Middleton, G.W., Smith, I.E., O'Brien, M.E.R., Norton, A., Hickish, T., Priest, K. and Spencer, L., 1998. Good symptom relief with palliative MVP mitomycin-C, vinblastine and cisplatin chemotherapy in malignant mesothelioma. Pneumologie, 52 (7), 432.
  • more information
• Makris, A., Powles, T.J., Ashley, S.E., Chang, J., Hickish, T., Tidy, V.A., Nash, A.G. and Ford, H.T., 1998. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol, 9 (11), 1179-1184.
  • more information
• Cunningham, D., Hickish, T.F. et al., 1998. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 352 (9138), 1413-1418.
  • more information
• Cunningham, D., Hickish, T. et al., 1998. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol, 102 (2), 495-502.
  • more information
• Middleton, G.W., Smith, I.E., O'Brien, M.E., Norton, A., Hickish, T., Priest, K., Spencer, L. and Ashley, S., 1998. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol, 9 (3), 269-273.
  • more information
• Beale, P., Judson, I., Hanwell, J., Berry, C., Aherne, W., Hickish, T., Martin, P. and Walker, M., 1998. Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients. Cancer Chemother Pharmacol, 42 (1), 71-76.
  • more information
• Hickish, T.F., Smith, I.E., Nicolson, M.C., Ashley, S., Priest, K., Spencer, L., Norman, A., Middleton, G. and O'Brien, M.E.R., 1998. A pilot study of MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in small-cell lung cancer. British Journal of Cancer, 77 (11), 1966-1970.
  • more information
• Hickish, T.F., Smith, I.E., O'Brien, M.E.R., Ashley, S. and Middleton, G., 1998. Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors. British Journal of Cancer, 78 (1), 28-33.
  • more information
• Iveson, T., Eggleton, S.P.H., Hickish, T., Cunningham, D., Maughan, T. and Harper, P., 1998. Irinotecan (CPT-11) in 5-FU pretreated advanced colorectal cancer: Results in 174 expanded access patients. ANNALS OF ONCOLOGY, 9, 36-37.
  • more information
• Mattia, E., Chichiarelli, S., Hickish, T., Gaeta, A., Mancini, C., Cunningham, D. and van Renswoude, J., 1997. Inhibition of in vitro proliferation of Epstein Barr Virus infected B cells by an antisense oligodeoxynucleotide targeted against EBV latent membrane protein LMP1. Oncogene, 15 (4), 489-493.
  • more information
• Webb, A., Hickish, T. et al., 1997. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol, 15 (1), 261-267.
  • more information
• Mainwaring, P.N., Nicolson, M.C., Hickish, T., Penson, R., Joel, S., Slevin, M. and Smith, I.E., 1997. Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy. Br J Cancer, 76 (12), 1636-1639.
  • more information
• Hickish, T.F., Smith, I.E., Ashley, S. and Middleton, G., 1996. Chemotherapy for elderly patients with lung cancer. Pneumologie, 50 (7), 503.
  • more information
• O'Brien, M.E., Milan, S., Cunningham, D., Jones, A.L., Nicolson, M., Selby, P., Hickish, T., Hill, M., Gore, M.E. and Viner, C., 1996. High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease--a pragmatic prognostic index. Br J Cancer, 73 (10), 1272-1277.
  • more information
• Powles, R., Raje, N., Horton, C., Mehta, J., Singhal, S., Hickish, T., Viner, C., Milan, S., Treleaven, J. and Cunningham, D., 1996. Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy. Leuk Lymphoma, 21 (5-6), 421-427.
  • more information
• Findlay, M., Young, H., Cunningham, D., Iveson, A., Cronin, B., Hickish, T., Pratt, B., Husband, J., Flower, M. and Ott, R., 1996. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol, 14 (3), 700-708.
  • more information
• Modjtahedi, H. et al., 1996. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br J Cancer, 73 (2), 228-235.
  • more information
• Powles, T.J., Hickish, T., Kanis, J.A., Tidy, A. and Ashley, S., 1996. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol, 14 (1), 78-84.
  • more information
• Nicolson, M., Webb, A., Cunningham, D., Norman, A., O'Brien, M., Hill, A. and Hickish, T., 1995. Cisplatin and protracted venous infusion 5-fluorouracil (CF)--good symptom relief with low toxicity in advanced pancreatic carcinoma. Ann Oncol, 6 (8), 801-804.
  • more information
• Powles, T.J. and Hickish, T., 1995. Tamoxifen therapy and carcinogenic risk. J Natl Cancer Inst, 87 (18), 1343-1345.
  • more information
• Hill, M., Norman, A., Cunningham, D., Findlay, M., Watson, M., Nicolson, V., Webb, A., Middleton, G., Ahmed, F. and Hickish, T., 1995. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol, 13 (9), 2317-2323.
  • more information
• Hickish, T.F., Smith, I.E., Ashley, S. and Middleton, G., 1995. Chemotherapy for elderly patients with lung cancer. The Lancet, 346 (8974), 580.
  • more information
• Powles, T.J. and Hickish, T., 1995. Breast cancer response to hormone replacement therapy withdrawal. Lancet, 345 (8962), 1442.
  • more information
• Eisen, T., Hickish, T., Smith, I.E., Sloane, J. and Eccles, S., 1995. Small-cell lung cancer. Report of a Meeting of POhysicians and Scientists at the Royal Marsden Hospital, Sutto, UK. The Lancet, 345 (8960), 1285-1289.
  • more information
• Hickish, T.F., Smith, I.E., Mlddleton, G. and Nicolson, M., 1995. Patient preference for extended palliative chemotherapy for non-small cell lung cancer. The Lancet, 345 (8953), 857-858.
  • more information
• Hill, M., Hickish, T. et al., 1995. Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity. Journal of Clinical Oncology, 13 (2), 387-395.
  • more information
• Hill, M., Hickish, T. et al., 1995. Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. Journal of Clinical Oncology, 13 (6), 1297-1302.
  • more information
• Powles, T.J. et al., 1995. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. Journal of Clinical Oncology, 13 (3), 547-552.
  • more information
• Ellis, P.A., Norman, A., Hill, A., O'Brien, M.E.R., Nicolson, M., Hickish, T. and Cunningham, D., 1995. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. European Journal of Cancer, 31 (10), 1594-1598.
  • more information
• McMaster, T.J., Hickish, T., Min, T., Cunningham, D. and Miles, M.J., 1994. Application of scanning force microscopy to chromosome analysis. Cancer Genet Cytogenet, 76 (2), 93-95.
  • more information
• Findlay, M., Cunningham, D., Norman, A., Mansi, J., Nicolson, M., Hickish, T., Nicolson, V., Nash, A., Sacks, N. and Ford, H., 1994. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol, 5 (7), 609-616.
  • more information
• Hickish, T.F. and Cunningham, D., 1994. Should induction chemotherapy be considered for all patients with gastric cancer? European Journal of Surgical Oncology, 20 (2), 185-186.
  • more information
• Hickish, T., Robertson, D., Clarke, P., Hill, M., di Stefano, F., Clarke, C. and Cunningham, D., 1994. Ultrastructural localization of BHRF1: an Epstein-Barr virus gene product which has homology with bcl-2. Cancer Res, 54 (10), 2808-2811.
  • more information
• Cunningham, D., Paz-Ares, L., Milan, S., Powles, R., Nicolson, M., Hickish, T., Selby, P., Treleavan, J., Viner, C. and Malpas, J., 1994. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol, 12 (4), 759-763.
  • more information
• Cunningham, D., Paz-Ares, L., Gore, M.E., Malpas, J., Hickish, T., Nicolson, M., Meldrum, M., Viner, C., Milan, S. and Selby, P.J., 1994. High-dose melphalan for multiple myeloma: long-term follow-up data. J Clin Oncol, 12 (4), 764-768.
  • more information
• McCready, V.R. and Hickish, T.F., 1994. Somatostatin imaging function. The Lancet, 343 (8898), 617.
  • more information
• O'Brien, M.E., Matutes, E., Cunningham, D., Hill, M., Emmett, E., Ellis, P.A., Milan, S., Hickish, T., Mercieca, J. and Catovsky, D., 1994. Fludarabine in lymphoproliferative disorders: the Royal Marsden Hospital experience. Leuk Lymphoma, 14 Suppl 2, 17-23.
  • more information
• Hill, M., Cunningham, D., MacVicar, D., Roldan, A., Husband, J., McCready, R., Mansi, J., Milan, S. and Hickish, T., 1993. Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. J Clin Oncol, 11 (11), 2273-2278.
  • more information
• Hickish, T., Cunningham, D., Colston, K., Millar, B.C., Sandle, J., Mackay, A.G., Soukop, M. and Sloane, J., 1993. The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. Br J Cancer, 68 (4), 668-672.
  • more information
• Hickish, T., Roldan, A., Cunningham, D., Mansi, J., Ashley, S., Nicolson, V., Gore, M.E., Catovsky, D. and Smith, I.E., 1993. EPIC: an effective low toxicity regimen for relapsing lymphoma. Br J Cancer, 68 (3), 599-604.
  • more information
• Scott-Mackie, P., Hickish, T., Mortimer, P., Sloane, J. and Cunningham, D., 1993. Calcipotriol and regression in T-cell lymphoma of skin. Lancet, 342 (8864), 172.
  • more information
• Powles, T.J., Hickish, T., Casey, S. and O'Brien, M., 1993. Hormone replacement after breast cancer. Lancet, 342 (8862), 60-61.
  • more information
• HICKISH, T., 1993. 2'-Chlorodeoxyadenosine : evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br J Cancer, 67, 139-143.
  • more information
• Hickish, T.F., Purvies, H., Mansi, J., Soukop, M. and Cunningham, D., 1991. Molecular monitoring of low grade non-hodgkin’s lymphoma by gene amplification. British Journal of Cancer, 64 (6), 1161-1163.
  • more information
• Hickish, T. and Cunningham, D., 1990. Gastrointestinal non-Hodgkin's lymphoma. Baillieres Clin Gastroenterol, 4 (1), 191-200.
  • more information
• Hickish, T., Colston, K.W., Bland, J.M. and Maxwell, J.D., 1989. Vitamin D deficiency and muscle strength in male alcoholics. Clin Sci (Lond), 77 (2), 171-176.
  • more information
• Hickish, T. and Cunningham, D., 1989. Detecting t(14;18) in paraffin-embedded lymphoma tissue. Lancet, 2 (8656), 218-219.
  • more information
• Hickish, T. and Cunningham, D., 1989. Detecting t(14;18) in paraffin-embedded lymphoma tissue. Lancet, 1 (8647), 1131-1132.
  • more information
• Cunningham, D., Hickish, T., Rosin, R.D., Sauven, P., Baron, J.H., Farrell, P.J. and Isaacson, P., 1989. Polymerase chain reaction for detection of dissemination in gastric lymphoma. Lancet, 1 (8640), 695-697.
  • more information
• Hickish, T., Cunningham, D., Haydock, A. and Coombes, R.C., 1989. Experience with intermediate-dose (110-120 mg/m2) epirubicin. Cancer Chemother Pharmacol, 24 (1), 61-64.
  • more information
• Hickish, T., Colston, K.W., Bland, J.M. and Maxwell, J.D., 1989. Vitamin D deficiency and muscle strength in male alcoholics. Clinical Science, 77 (2), 177-182.
  • more information
• CUNNINGHAM, D., HICKISH, T., ROSIN, R.D., SAUVEN, P., BARON, J.H., FARRELL, P.J. and ISAACSON, P., 1989. POLYMERASE CHAIN-REACTION FOR DETECTION OF DISSEMINATION IN GASTRIC LYMPHOMA. LANCET, 1 (8640), 695-697.
  • more information
• HICKISH, T. and CUNNINGHAM, D., 1989. DETECTING T(14-18) IN PARAFFIN-EMBEDDED LYMPHOMA TISSUE. LANCET, 2 (8656), 218-219.
  • more information
• HICKISH, T. and CUNNINGHAM, D., 1989. DETECTING T(14-18) IN PARAFFIN-EMBEDDED LYMPHOMA TISSUE. LANCET, 1 (8647), 1131.
  • more information
• Isles, S.R., Hickish, T. and Cunningham, D., 1988. Chemotherapy related pulmonary embolus recognized. BMJ, 297 (6652), 854.
  • more information
• Smedley, F., Hickish, T., Taube, M., Yale, C., Leach, R. and Wastell, C., 1988. Perforated duodenal ulcer and cigarette smoking. J R Soc Med, 81 (2), 92-94.
  • more information
• Smedley, F.H. and Hickish, T., 1986. Non-steroidal anti-inflammatory drugs and peptic ulcer perforation. Gut, 27 (1), 114.
  • more information

Chapters

• Cidón, E.U. and Hickish, T., 2014. Stem cells in colon cancer. Stem Cells in Cancer: Should We Believe or Not?. 127-147.
  • more information

Conferences

• Thomas, D., Hickish, T. et al., 2020. Impact of the Oncotype DX breast cancer assay on treatment decisions in a UK population of patients with oestrogen receptor positive early breast cancer with 1-3 lymph nodes positive who are candidates for chemotherapy, but for whom the benefits are uncertain - Interim results. CANCER RESEARCH, 80 (4).
  • more information
• Cidon, E.U., Alonso, P., Hickish, T., Goulbourne, S. and Tyler, A., 2020. Special mouthwash and chronology of oral mucositis in previous cycle to prevent future episodes. ANNALS OF ONCOLOGY, 31, S128.
  • more information
• Jones, R., Hickish, T. et al., 2020. Vandetanib plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER positive breast cancer (FURVA): A randomised, double-blind, placebo-controlled, phase II trial. ANNALS OF ONCOLOGY, 31, S1151.
  • more information
• Una Cidon, E., Alonso, P., Hickish, T., Tyler, A. and Goulbourne, S., 2019. Preventing oral mucositis by using its chronology in prior cycle and a special mouthwash. Annals of oncology : official journal of the European Society for Medical Oncology, 30, iv66-iv67.
  • more information
  • view in BU repository
• Pogue-Geile, K.L., Hickish, T. et al., 2019. Association of colon cancer (CC) molecular signatures with prognosis and oxaliplatin prediction benefit in the MOSAIC Trial (Multicenter International Study of Oxaliplatin/5FU-LV in the Adjuvant Treatment of Colon Cancer). JOURNAL OF CLINICAL ONCOLOGY, 37 (15).
  • more information
• Eccles, B.K., Hickish, T. et al., 2018. Prospective DPYD testing in colorectal cancer patients in a realworld UK population. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii187.
  • more information
• Auclin, E., Andre, T., Taieb, J., Banzi, M., van Laethem, J.L., Tabernero, J., Hickish, T., de Gramont, A. and Vernerey, D., 2018. Postoperative carcinoembryonic antigen (CEA) association with survival and oxaliplatin benefit in stage II colon cancer (CC): Post hoc analysis of the MOSAIC trial. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii154.
  • more information
• Jeffery, J., Murphy, J.L., Hewitt-Taylor, J. and Hickish, T., 2018. Longitudinal study of energy and macronutrient intake during the first year following treatment for early stage breast cancer. PROCEEDINGS OF THE NUTRITION SOCIETY, 77 (OCE1), E10.
  • more information
• Auclin, E., Hickish, T. et al., 2018. Association of postoperative carcinoembryonic antigen (CEA) levels with survival in stage III colon cancer (CC): Post hoc analysis of the MOSAIC and PETACC-8 studies. JOURNAL OF CLINICAL ONCOLOGY, 36 (15).
  • more information
• Hickish, T., Mohanty, P., Michael, S., Shivaswamy, S., Sunley, K., Varshney, A., Martin, R. and Simard, J., 2017. Modulation of platelet levels by an anti-IL-1α antibody (MABp1) in advanced colorectal cancer patients. EUROPEAN JOURNAL OF CANCER, 72, S70.
  • more information
• Vaughan, N., Dubey, V.N., Hickish, T. and Cole, J., 2017. A smart device to substitute the neurothesiometer. Proceedings of the ASME Design Engineering Technical Conference, 3.
  • more information
  • view in BU repository
• Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Waldron-Lynch, M., Eng-Wong, J., Kirk, S. and Cortes, J., 2017. Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiac safety study (TRYPHAENA). CANCER RESEARCH, 77.
  • more information
• Bridgewater, J., Hickish, T. et al., 2017. Perioperative chemotherapy with or without cetuximab in patients (pts) with resectable colorectal liver metastasis (CRLM): Mature analysis of overall survival (OS) in the New EPOC randomised controlled trial. ANNALS OF ONCOLOGY, 28.
  • more information
• Neoptolemos, J.P., Hickish, T. et al., 2017. Biomarker prediction of efficacy to vandetanib plus gemcitabine in a phase II double blind multicenter randomized placebo controlled trial in locally advanced or metastatic pancreatic carcinoma. JOURNAL OF CLINICAL ONCOLOGY, 35.
  • more information
• Wyrwicz, L., Hickish, T. et al., 2017. MABp1 to improve clinical outcomes of patients with symptomatic refractory metastatic colorectal cancer patients: Per-protocol population analysis of phase III study (P1026). JOURNAL OF CLINICAL ONCOLOGY, 35.
  • more information
• Hickish, T., Andre, T., Wyrwicz, L., Saunders, M., Sarosiek, T., Nemecek, R., Kocsis, J., Stecher, M. and de Gramont, A., 2016. A pivotal phase 3 trial of MABp1 in advanced colorectal cancer. ANNALS OF ONCOLOGY, 27, 128.
  • more information
• Earl, H.M., Hickish, T. et al., 2016. Disease-free (DFS) and overall survival (OS) at 3.4 years (yrs) for neoadjuvant bevacizumab (Bev) added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC), for women with HER2 negative early breast cancer: The ARTemis trial. JOURNAL OF CLINICAL ONCOLOGY, 34 (15).
  • more information
• Hickish, T. and Purandare, L., 2015. A pilot study to assess the safety and feasibility of pre-chemotherapy assessment using telemedicine. In: Phi Mu Chapter Biannual Conference 19 June 2015 Leeds.
  • more information
• Abbey, G., Thompson, S.B.N., Hickish, T. and Heathcote, D., 2015. A meta-analysis of prevalence rates and moderating factors for cancer-related post-traumatic stress disorder. Psycho-Oncology, 24 (4), 371-381.
  • more information
  • view in BU repository
• Cidon, E.U., Alonso, P., Needham, S. and Hickish, T., 2015. First cycle dose calculation in obese patients with colorectal cancers. ANNALS OF ONCOLOGY, 26.
  • more information
• Earl, H.M., Hickish, T. et al., 2015. ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy for patients with HER2-negative early breast cancer. CANCER RESEARCH, 75.
  • more information
• Hickish, Hickish, T. et al., 2014. ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer: primary endpoint – pathological complete response (pCR). In: NCRI Cancer Conference in the Clinical Trials Showcase 2-5 November 2014 Liverpool.
  • more information
• Bridgewater, J., Hickish, T. et al., 2014. Analysis of progression free survival in the New EPOC study in an all RAS wild-type population. In: ESMO 2014 Congress 26-30 September 2014 Madrid, Spain.
  • more information
• Moyers-Ruiz, L., Thompson, S.B.N., Hickish, T. and Mayers, A., 2014. Prospective memory and cognitive impairment in breast cancer patients. In: 4th International Conference on Prospective Memory 26-30 May 2014 Suor Orsola Benincasa University, Naples.
  • more information
• Schroeder, J.W., Dubey, V., Hickish, T. and Cole, T., 2014. Intelligent Agent Based Software Architecture of a Wearable Electrotactile Feedback System for Balance Improvement. In: 2014 International Academic Conference on Engineering, Internet and Technology 12-13 December 2014 Prague. Proceedings of IAC-ElaT 2014.
  • more information
• Una Cidon, E., Hickish, T. and Alonso, P., 2014. Cardiac Toxicity with Fluoropyrimidines in Colorectal Cancer. In: ESMO World GI 2014 25-28 June 2014 Barcelona, Spain. Annals of Oncology, 2 (25).
  • more information
• Una Cidon, E., Hickish, T. and Alonso, P., 2014. Cetuximab as Monotherapy in Elderly Patients with Metastatic Colorectal Cancer. In: ESMO World GI 2014 25-28 June 2014 Barcelona, Spain. Annals of Oncology, 2 (25).
  • more information
• André, T., Hickish, T. et al., 2014. MOSAIC study: Actualization of Overall Survival (OS) with 10 years follow up and evaluation of BRAF by GERCOR and MOSAIC investigators. In: ESMO 2014 26-30 September 2014 Madrid, Spain. Annals of Oncology, 4 (25).
  • more information
• Cameron, D., Spector, N., Gomez, H., Hickish, T., Vandat, L., Kim, S.B., Sheldon, E., El-Hariry, I., Perez, E. and Awada, A., 2014. Targeting HSP90 in breast cancer: ENCHANT-1 (NCT01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic HER2 positive or triple negative breast cancer (TNBC). EUROPEAN JOURNAL OF CANCER, 50, S98.
  • more information
• Schroeder, J.W., Dubey, V., Hickish, T. and Cole, T., 2014. Intelligent Agent Based Software Architecture of a Wearable Electrotactile Feedback System for Balance Improvement. In: International Academic Conference on Engineering, Internet and Technology 12-13 December 2014 Prague. Proceedings of IAC-ElaT 2014.
  • more information
• Earl, H., Hickish, T. et al., 2014. ARTemis: A randomised trial of bevacizumab with neo-adjuvant chemotherapy (NACT) for patients with HER2-negative early breast cancer: primary endpoint – pathological complete response (pCR). In: NCRI Cancer Conference in the Clinical Trials Showcase 2-5 November 2014 Liverpool.
  • more information
• Petricoin, E.F., Wulfkuhle, J., Hickish, T., El-Hariry, I., Reichert, V., Vukovic, V.M., Cameron, D.A., Awada, A. and Spector, N., 2014. Gene expression and proteomic analysis to identify predictive biomarkers of response in the ENCHANT-1 Trial (NCT01677455), a Phase 2 Proof of Concept study evaluating first-line ganetespib monotherapy in women with metastatic HER2 positive or triple negat. CANCER RESEARCH, 74 (19).
  • more information
• Abbey, G., Thompson, S.B.N., Hlickish, T. and Heathcota, D., 2014. A meta-analysis of prevalence rates and moderating factors for cancer related post-traumatic stress disorder. JOURNAL OF CLINICAL ONCOLOGY, 32 (15).
  • more information
• Cameron, D.A., Hickish, T. et al., 2014. Targeting HSP90 in breast cancer: Enchant-1 (NCT01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 32 (15).
  • more information
• Moyers-Ruiz, L., Thompson, S.B.N., Hickish, T. and Mayers, A., 2013. Cognitive decline as a result of impaired sleep and glucose levels during chemotherapy treatment in breast cancer patients. In: American Society of Clinical Oncology 31 May-4 June 2013 McCormick Place, Chicago, USA.
  • more information
• Flejou, J.-F., Hickish, T. et al., 2013. Effect of adding oxaliplatin to adjuvant 5-fluorouracil/leucovorin (5FU/LV) in patients with defective mismatch repair (dMMR) colon cancer stage II and III included in the MOSIAC study. JOURNAL OF CLINICAL ONCOLOGY, 31 (15).
  • more information
• Primrose, J.N., Hickish, T. et al., 2013. A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study. JOURNAL OF CLINICAL ONCOLOGY, 31 (15).
  • more information
• Schroeder, J.W., Dubey, V.N., Hickish, T., Cole, J., Mecheraoui, C. and Swain, I., 2012. Applications of electrical stimulation and electrotactile feedback in human spaceflight. In: 63rd International Astronautical Congress 1-5 October 2012 Naples, Italy.
  • more information
• Schroeder, J.W., Dubey, V.N., Hickish, T.F. and Cole, J., 2012. Wearable Electrocutaneous Feed-back System: A Smart Device to Compensate for Sensation Loss. In: Design of Medical Devices 10-12 April 2012 Minneapolis, Minnesota, USA.
  • more information
• Schroeder, J.W., Dubey, V.N., Hickish, T.F. and Cole, J., 2012. Case Study on Repeatability of a Threshold-Based Calibration Method for Electrocutaneous Feedback Systems. In: Design of Medical Devices 10-12 April 2012 Minneapolis, Minnesota, USA.
  • more information
• Moyers-Ruiz, L., Thompson, S.B.N. and Hickish, T., 2012. Prospective and working memory decline in breast cancer patients during chemotherapy. In: International Cognition & Cancer Task Force 15-17 March 2012 Espace Saint-Martin, Paris, France.
  • more information
• Moyers-Ruiz, L., Thompson, S.B.N. and Hickish, T., 2012. Longitudinal study of prospective and working memory decline in breast cancer patients undergoing chemotherapy. In: British Psychosocial Oncology Society Annual Conference 19-20 January 2012 Metropole Hotel, Leeds.
  • more information
• Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Hegg, R., Tausch, C., Seo, J.H., Tsai, Y.F., McNally, V. and Cortes, J., 2012. Pertuzumab and Trastuzumab in Combination with an Anthracycline-containing or an Anthracycline-free Standard Chemotherapy in the Neoadjuvant Treatment of HER2-positive Breast Cancer (TRYPHAENA). EUROPEAN JOURNAL OF CANCER, 48, S96.
  • more information
• Moyers-Ruiz, L., Hickish, T. and Thompson, S., 2012. Prospective and working memory decline as a result of impaired sleep and/or impared blood glucose in breast cancer patients during chemotherapy treatment. JOURNAL OF CLINICAL ONCOLOGY, 30 (15).
  • more information
• Hickish, T., Tseng, L.-M., Mehta, A.O., Tsang, J., Kovalenko, N., Udovitsa, D., Pelling, K., Uttenreuther-Fischer, M.M. and Huang, C.-S., 2012. LUX-breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatanib (L). JOURNAL OF CLINICAL ONCOLOGY, 30 (15).
  • more information
• Schroeder, J., Dubey, V., Hickish, T. and Cole, J., 2012. Creation of Artificial Sensation by Tactile Sensing and Intelligent Stimulation of Sensory Nerves. In: DEC Researchers Poster Conference. December 2012 Bournemouth.
  • more information
• Schroeder, J., Dubey, V., Hickish, T. and Cole, J., 2012. Multisensory Intelligent Feedback System for Sensory Substitution using Electrical Stimulation. In: DEC Researchers Poster Conference 2012 Bournemouth.
  • more information
• Hickish, T., Mehta, A., Jain, M., Huang, C.-S., Kovalenko, N., Udovitsa, D., Pemberton, K., Uttenreuther-Fischer, M. and Tseng, L.-M., 2012. LUX-Breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab and/or lapatinib. CANCER RESEARCH, 72.
  • more information
• Shipway, R., Jones, I. and Holloway, I., 2011. Healthy Options? Putting your (Running) body on the line. International Sociology of Sport Association.
  • more information
• Schroeder, J.W., Dubey, V.N., Hickish, T.F. and Cole, J., 2011. Electrocutaneous feedback system to improve the estimation of pressure applied to the foot. In: International Conference on Biomedical Electronics and Devices (BIODEVICES 2011) 26-29 January 2011 Rome, Italy.
  • more information
• Schroeder, J., Dubey, V., Hickish, T. and Cole, J., 2011. Electrocutaneous Feedback System for Patients with Loss of Sensation in their Feet. In: Salisbury FES User Day 2011 Salisbury.
  • more information
• Schroeder, J.W., Dubey, V.N., Hickish, T. and Cole, J., 2011. Electrocutaneous Feedback System to Improve the Estimation of Pressure Applied to the Foot. BIODEVICES, 386-390 SciTePress.
  • more information
• Schneeweiss, A., Hickish, T. et al., 2011. Neoadjuvant Pertuzumab and Trastuzumab Concurrent or Sequential with an Anthracycline-Containing or Concurrent with an Anthracycline-Free Standard Regimen: A Randomized Phase II Study (TRYPHAENA). CANCER RESEARCH, 71.
  • more information
• Seymour, M.T., Hickish, T. et al., 2011. Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). JOURNAL OF CLINICAL ONCOLOGY, 29 (15).
  • more information
• Wong, R., Saffery, C., Barbachano, Y., Chau, I., Valle, J., Hickish, T., Mudan, S., Khan, A., Chua, Y.J. and Cunningham, D., 2009. BOXER: A multicentre phase II trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with liver-only metastases from colorectal cancer unsuitable for upfront resection. EJC SUPPLEMENTS, 7 (2), 344-345.
  • more information
• Purandare, L., Baker, R. and Hickish, T., 2009. Can oncology nurses and other allied health professionals learn to treat post traumatic stress disorder in cancer survivors. EJC SUPPLEMENTS, 7 (2), 196.
  • more information
• Purandare, L., Hickish, T., Astras, G., Penfold, S., Thomas, F. and Kerr, D., 2009. Impaired glucose tolerance in non-diabetic women during adjuvant chemotherapy for breast cancer. EJC SUPPLEMENTS, 7 (2), 309.
  • more information
• Hickish, T., Wheatley, D., Lin, N., Carey, L., Houston, S., Mendelson, D., Solca, F., Uttenreuther-Fischer, M., Jones, H. and Winer, E., 2009. Use of BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor To Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab. CANCER RESEARCH, 69 (24), 785S.
  • more information
• Earl, H.M., Vallier, A., Hiller, L., Fenwick, N., Iddawela, M., Hughes-Davies, L., Provenzano, E., McAdam, K., Hickish, T. and Caldas, C., 2009. Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR). JOURNAL OF CLINICAL ONCOLOGY, 27 (15).
  • more information
• Hickish, T., Wheatley, D., Lin, N., Carey, L., Houston, S., Mendelson, D., Solca, F., Uttenreuther-Fischer, M., Jones, H. and Winer, E., 2009. Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab. JOURNAL OF CLINICAL ONCOLOGY, 27 (15).
  • more information
• de Gramont, A. et al., 2007. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. United States. J Clin Oncol, 25 (22), 3224-3229.
  • more information
• de Gramont, A., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Bonetti, A., Clingan, P., Lorenzato, C. and Andre, T., 2007. FOLFOX4 in adjuvant treatment of colon cancer: Survival results from the mosaic trial. ANNALS OF ONCOLOGY, 18, VII23.
  • more information
• Chau, I., Starling, N., Cunningham, D., Oates, J., Iveson, T., Nicolson, M., Hawkins, R., Hickish, T., Seymour, M. and Norman, A., 2007. Does histology influence outcome in advanced oesophagogastric (OG) cancer? Individual patient data from 1,680 patients on three randomised controlled trials (RCT). JOURNAL OF CLINICAL ONCOLOGY, 25 (18).
  • more information
• Cassidy, J., Bjarnason, G.A., Hickish, T., Topham, C., Provencio, M., Bodoky, G., Landherr, L., Koralewski, P., Lopez-Vivanco, G. and Said, G., 2006. Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC). JOURNAL OF CLINICAL ONCOLOGY, 24 (18), 147S.
  • more information
• de Gramont, A., Hickish, T. et al., 2005. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer:: Efficacy results with a median follow-up of 4 years. JOURNAL OF CLINICAL ONCOLOGY, 23 (16), 246S.
  • more information
• Hickish, T., Boni, C., Navarro, M., Tabernero, J., Topham, C., Bonetti, A., Clingan, P., Figer, A., Andre, T. and De Gramont, A., 2004. FOLFOX4 as adjuvant treatment for stage II colon cancer (CC): Subpopulation data from the MOSAIC trial. JOURNAL OF CLINICAL ONCOLOGY, 22 (14), 274S.
  • more information
• Norman, A.R., Chau, I., Iveson, T., Hill, M., Hickish, T., Lofts, F., Jodrell, D., Shellito, P., Oates, J. and Cunningham, D., 2004. Longitudinal quality of life (QoL) and quality adjusted survival (QAS) in a randomised controlled trial (RCT) comparing bolus (24 weeks) vs. protracted venous infusion (PVI 12 weeks) 5-FU as adjuvant chemotherapy for colorectal cancer (CRC). JOURNAL OF CLINICAL ONCOLOGY, 22 (14), 276S.
  • more information
• Trumper, M.J., Norman, A.R., Ross, P.J., Cunningham, D., Hawkins, R., Seymour, M., Harper, P., Iveson, T., Nicholson, M. and Hickish, T., 2004. Patients aged 70 or older (≥ 70) with advanced oesophagogastric cancer (OGC) experience similar benefits from palliative chemotherapy compared to younger patients. JOURNAL OF CLINICAL ONCOLOGY, 22 (14), 318S.
  • more information
• Starling, N., Chau, I., Norman, A.R., Tait, D., Iveson, T., Hill, M., Hickish, T., Lofts, F., Jodrell, D. and Cunningham, D., 2004. A randomised comparison between six months of bolus fluorouracil (5-FUV leucovorin (LV) and twelve weeks of protracted venous infusion (PVI) 5-FU as adjuvant treatment in colorectal cancer: An update with 5 years' follow-up. JOURNAL OF CLINICAL ONCOLOGY, 22 (14), 250S.
  • more information
• Harper-Wynne, C., Sumpter, K., Cunningham, D., Norman, A., Oates, J., Durrant, C., Iveson, T., Nicholson, M., Hickish, T. and Hill, M., 2003. Randomised, multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: Confirmation of dose escalation. BRITISH JOURNAL OF CANCER, 88, S22.
  • more information
• Powles, R., Hickish, T. et al., 1998. A randomised trial of maintenance interferon following high dose chemotherapy in multiple myeloma: Results 51/2 years after the accrual of the last patient. BONE MARROW TRANSPLANTATION, 21, S209.
  • more information
• Powles, R., Hickish, T. et al., 1997. A randomised trial of maintenance interferon following high dose chemotherapy in multiple myeloma: Results 5 1/2 years after accrual of the last patient. BLOOD, 90 (10), 1588.
  • more information
• Raje, N., Hickish, T. et al., 1995. Peripheral blood transplants followed by maintenance interferon in myeloma. EUROPEAN JOURNAL OF CANCER, 31A, 814.
  • more information
• Singhal, S., Powles, R., Cunningham, D., Hickish, T., Middleton, G., Raje, N., Viner, C. and Mehta, J., 1995. Second autografts for relapsed myeloma. EUROPEAN JOURNAL OF CANCER, 31A, 801.
  • more information
• Raje, N., Powles, R., Hickish, T., Gore, M., Milan, S., Mehta, J., Singhal, S., Viner, C., Treleaven, J. and Cunningham, D., 1995. VAMP/C-VAMP infusional chemotherapy as induction treatment for previously untreated multiple myeloma. EUROPEAN JOURNAL OF CANCER, 31A, 799.
  • more information
• Powles, R., Raje, N., Hickish, T., Middleton, G., Milan, S., Mehta, J., Singhal, S., Viner, C., Treleaven, J. and Cunningham, D., 1995. Single centre results of therapy including autografts in previously untreated myeloma. EUROPEAN JOURNAL OF CANCER, 31A, 797.
  • more information
• Middleton, G.W., Mehta, J., Porter, H., Miller, B.C., Bell, J.A., Raje, N., Hickish, T., Shepherd, V. and Powles, R.L., 1995. Comparison of two stem cell mobilization and harvesting regimens for peripheral blood stem cell (PBSC) transplantation in multiple myeloma (MM). EUROPEAN JOURNAL OF CANCER, 31A, 246.
  • more information
• Raje, N., Powles, R., Hickish, T., Horton, C.A.P., Milan, S., Mehta, J., Singhal, S., Viner, C., Treleaven, J. and Cunningham, D., 1995. Outcome of relapsed/resistant multiple myeloma: The Royal Marsden experience. BLOOD, 86 (10), 3352.
  • more information
• Raje, N., Powles, R., Hickish, T., Milan, S., Horton, C., Mehta, J., Singhal, S., Treleaven, J. and Cunningham, D., 1995. Beta 2 microglobulin levels in patients of myeloma following high dose treatment and interferon maintenance. BLOOD, 86 (10), 3351.
  • more information
• Powles, R., Raje, N., Milan, S., Hickish, T., Mehta, J., Singhal, B., Viner, C., Treleaven, J. and Cunningham, D., 1995. Prognostic factors in multiple myeloma. BLOOD, 86 (10), 733.
  • more information
• Powles, R., Raje, N., Milan, S., Mehta, J., Singhal, S., Hickish, T., Viner, C., Treleaven, J. and Cunningham, D., 1995. Impact of induction chemotherapy followed by high dose treatment in previously untreated myeloma: A since centre experience. BLOOD, 86 (10), 732.
  • more information
• Raje, N., Powles, R., Milan, S., Hickish, T., Mehta, J., Singhal, S., Viner, C., Treleaven, J. and Cunningham, D., 1995. Induction treatment with VAMP/C-VAMP infusional chemotherapy in previously untreated myeloma. BLOOD, 86 (10), 731.
  • more information
• CLARKE, P., HICKISH, T., ROBERTSON, D., HILL, M., DISTEFANO, F. and CONNINGHAM, D., 1994. IN-VIVO EXPRESSION AND LOCALIZATION OF BHRF-1, AN EPSTEIN-BARR-VIRUS (EBV) ENCODED BCL-2 HOMOLOG. JOURNAL OF CELLULAR BIOCHEMISTRY, 230.
  • more information
• CUNNINGHAM, D., HILL, M.E., MILAN, S., MANSI, J.L., SMITH, I.E., CATOVSKY, D., GORE, M., OBRIEN, M.E.R., NICOLSON, M. and HICKISH, T., 1994. VEEP CHEMOTHERAPY FOR ADULT HODGKINS-DISEASE - ASSESSMENT OF EFFICACY AND GONADAL AND CARDIAC TOXICITY. BLOOD, 84 (10), A162.
  • more information
• CUNNINGHAM, D., OBRIEN, M.E.R., HILL, M., MILAN, S., NICOLSON, M., JONES, A.L., VINER, C. and HICKISH, T., 1994. HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW TRANSPLANT IN HODGKINS-DISEASE - THE ROYAL-MARSDEN-HOSPITAL EXPERIENCE. BLOOD, 84 (10), A162.
  • more information
• ADSHEAD, F.J., HICKISH, T., PURVIES, H., CUNNINGHAM, D., SMITH, I.E. and MILLAR, J.L., 1991. INTERLEUKIN-3 GENE-EXPRESSION IN CYCLOPRIMED BONE-MARROW. EXPERIMENTAL HEMATOLOGY, 19 (6), 523.
  • more information
• HICKISH, T., SOUKOP, M., MILLAR, B.C., MCELWAIN, T.J. and CUNNINGHAM, D., 1990. GROWTH MODULATION OF 2 LYMPHOMA CELL-LINES BY A NOVEL CALCITRIOL ANALOG MC903. BRITISH JOURNAL OF CANCER, 62 (3), 493-494.
  • more information
• HICKISH, T., SOUKOP, M., MCELWAIN, T.J. and CUNNINGHAM, D., 1990. DISEASE ASSESSMENT WITH THE POLYMERASE CHAIN-REACTION (PCR) IN FOLLICULAR SMALL CLEAVED CELL LYMPHOMA. BRITISH JOURNAL OF CANCER, 62 (3), 485.
  • more information
• CUNNINGHAM, D., HICKISH, T., ROSIN, D., SAUVEN, P., BARON, H., FARRELL, P.J. and ISAACSON, P., 1989. PCR USED TO DETECT DISSEMINATION IN GASTRIC LYMPHOMA - IMPLICATIONS FOR TREATMENT. BRITISH JOURNAL OF CANCER, 60 (3), 447.
  • more information
• HICKISH, T., JOHNSON, M., COLSTON, K. and MAXWELL, J.D., 1986. MUSCLE STRENGTH AND VITAMIN-D STATUS IN MALE-ALCOHOLICS. CLINICAL SCIENCE, 71, P86.
  • more information

Patents

• Hickish, T., Dubey, V.N., Vaughan, N. and Cole, J.. Neuropathy Assessment Device. Patent number PCT/GB2016/051405.
  • more information
• 3. Schroeder, J.W., Dubey, V., Hickish, T.F. and Cole, J.. Electrotactile feedback system to compensate for sensation loss. Patent number 1109560.1.
  • more information

PhD Students

• Ejike Thankgod Ezeh. Web-Based Information Tool for People withAdvanced Cancer IRAS no:252843
• Mohammad Naiseh. Explainable AI in Healthcare

External Responsibilities

• Dorset Cancer Centre c/o Royal Bournemouth and Poole Hospitals, Consultant Medical Oncologist
• iQHealth Tech, Medical Director

Memberships

• Royal College of Physicians, Fellow,